zimeldine and Sleep-Initiation-and-Maintenance-Disorders

The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

Topics: Adolescent; Adult; Aged; Amitriptyline; Brompheniramine; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; Middle Aged; Pyridines; Sleep Initiation and Maintenance Disorders; Zimeldine

In a double-blind trial of the effect of zimelidine on weight and appetite 24 obese patients were allocated at random to receive either zimelidine or placebo for eight weeks followed by the alternative treatment for eight weeks. Possible adverse effects were elicited by asking patients at weekly intervals whether they had experienced any symptoms or ailments and recording all such "events" on a special form. A conventional checklist of symptoms was also used. Among 19 patients who completed the trial the two methods of recording yielded similar patterns of events. Of symptoms not on the checklist, insomnia was more common during treatment with zimelidine. Event recording was found to be a practicable and convenient method of detecting possible adverse effects.

Topics: Adult; Appetite; Body Weight; Brompheniramine; Clinical Trials as Topic; Data Collection; Double-Blind Method; Female; Humans; Pyridines; Sleep Initiation and Maintenance Disorders; Zimeldine

Changes in diagnostic criteria have shown a trend towards a broader definition of depression. Thus, a number of patients who would previously have been considered to be suffering from anxiety states are now classified as having major depressive illness according to the criteria of the Diagnostic Statistical Manual III. Despite this, such patients show a good response to antidepressant drugs (compared to placebo) if their severity of depression is above 15 on the Hamilton depression scale. It therefore seems likely that there is a common biological substrate underlying both anxiety states and depressive illness, but this issue remains somewhat controversial. The suggestion that the 5-HT system is involved in the mediation of anxiety is considered. Further evidence is required before definite conclusions can be drawn, but it seems clear that anxiolytic activity is not dependent on sedative properties.

Topics: Amitriptyline; Anxiety Disorders; Depressive Disorder; Humans; Serotonin; Sleep Initiation and Maintenance Disorders; Zimeldine